Pharmaceutical company Amneal Pharmaceuticals Inc (NYSE:AMRX) reported on Monday the receipt of the Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for generic TobraDex (tobramycin/dexamethasone) in 0.3%/0.1% for treating bacterial ocular infection.
With the approval of TobraDex (tobramycin/dexamethasone) in 0.3%/0.1%, the company said it adds another complex ophthalmic product to its generics portfolio.
TobraDex is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists, added the company.
US annual sales for dexamethasone and tobramycin ophthalmic suspension, including the brand TobraDex, for the 12 months ended May 2021 were approximately USD118m, as reported by IQVIA.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream